Floatz logo

Humax-Cd20

Non-Hodgkin's Lymphoma

Michael John Robertsonmonoclonal_antibodyPhase 3Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
58/ 100
Competitive Position
73/ 100

Competitive context

411 Active assets in the Non-Hodgkin's Lymphoma cohort.

Asset / SponsorPhaseRating
CYCLOSPORIN A
Memorial Sloan Kettering Cancer Center
Phase 3BBB
PEGASPARGASE
Ciusss de L'Est de l'Île de Montréal
Phase 4BBB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Mwanasha Merrill, MD
Phase 3BBB
Inno-206
National Cancer Institute (NCI)
Phase 4BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BBB

View all 50 →

Same molecule, other indications

Humax-Cd20 is also rated in:

B-cell chronic lymphocytic leukemiaDormant
BBB
Indicative ·
78 / 100
View asset →
relapsing-remitting multiple sclerosisDormant
BBB
Indicative ·
74 / 100
View asset →
diffuse large B-cell lymphomaDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →